| Objective:Gastric cancer is one of the most common malignant tumor, mortality rates in a malignant tumor2. But there is no uniform standard chemotherapy regimen for advanced gastric cancer.This study aimed to compare the efficacy and adverse reactions of two different chemotherapeutic regimens. In particular, chemotherapy with paclitaxel liposome was administered in combination with either S-1or oxaliplatin as the first-line therapy of advanced gastric cancer. Methods:The date of118cases of pathologically confirmed advanced gastric cancer from May2011to February2013were collected in the Oncological Department of The Affiliated Tumor Hospital of Xinjiang Medical University,A total of118patients with advanced gastric cancer were randomly divided into groups A (61cases) and B (57cases). In group A, paclitaxel liposome combined with S-1was administered; in group B, paclitaxel liposome combined with oxaliplatin was applied. The short-term efficacy, adverse reactions, Karnofsky performance status score, median time to progression (mTTP), and median overall survival (mOS) of the two groups were observed and compared. Results:No significant differences were observed in the objective response rate, disease control rate, and mTTP between groups A and B (31.1%vs.29.8%,75.4%vs.71.9%,4.2months vs.3.8months; P>0.05). The mOS rates were10.5and8.9months in groups A and B, respectively, with statistically significant differences (P=0.006). The incidence of degrees Ⅲ to Ⅳ diarrhea and peripheral nerve toxicity was significantly higher in group B than in group A (P<0.05). No statistical differences were found between the two groups in terms of other side effects. Conclusion: The results of near-term therapeutic effect and mTTP were similar in the two groups. Group A regimen could be more effective than group B in terms of mOS. The incidence of peripheral neuropathy and degrees Ⅲ to Ⅳ diarrhea was significantly lower in group A than in group B. |
PDF Full Text Request